Quantitative assessment of promoter methylation profiles in thyroid neoplasms

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4011-4018

  Hoque, M O ^a   Rosenbaum, E ^a   Westra, W H ^a   Xing, M ^a   Ladenson, P ^a   Zeiger, M A ^a   Sidransky, D ^a   Umbricht, C B ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CALCITONIN; DEATH ASSOCIATED PROTEIN KINASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; MARKER; PROTEIN P16; PROTEIN S 100; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; THYROTROPIN RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EPIGENETICS; GENE MUTATION; GENE SILENCING; HOSPITAL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METHYLATION; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; THYROID ADENOMA; THYROID CANCER; THYROID GLAND; THYROID HYPERPLASIA; THYROID TUMOR;

CELL LINE, TUMOR; DNA METHYLATION; HUMANS; MUTATION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 23044451135     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0313     Document Type: Article

References (63)

1. Gharib H, Goellner JR 1993 Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 118:282-289
2. HCIA I 1996 National Link Study 1995. Baltimore: Health Care Investment Analysts
3. Herman JG, Baylin SB 2003 Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054
4. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB 1996 Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826
5. Jones PA, Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428
6. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, Califano JA, Sidransky D 2004 Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 64:5511-5517
7. Topaloglu O, Hoque MO, Tokumaru Y, Lee J, Ratovitski E, Sidransky D, Moon CS 2004 Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10:2284-2288
8. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D 2004 Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 64:1664-1668
9. Xing M, Usadel H, Cohen Y, Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, Ladenson PW, Sidransky D 2003 Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 63:2316-2321
10. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C, Sidransky D 2004 Quantitative RARβ2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 10:4010-4014
11. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WB, Sidransky D 2001 Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7:2727-2730
12. Esteller M, Corn PG, Baylin SB, Herman JG 2001 A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229
13. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S 2001 Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357:1335-1336
14. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S 2001 Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 61:2782-2787
15. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB 2004 Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2α expression during progression of breast cancer. Cancer Res 64:1611-1620
16. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R 2002 Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62:3698-3701
17. Huang Y, de la Chapelle A, Pellegata NS 2003 Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 104:735-744
18. Hawthorn L, Stein L, Varma R, Wiseman S, Loree T, Tan D 2004 TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck 26:1069-1083
19. Nishimura R, Yokose T, Mukai K 1997 S-100 protein is a differentiation marker in thyroid carcinoma of follicular cell origin: an immunohistochemical study. Pathol Int 47:673-679
20. Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A 2004 S100A4 expression is an early event of papillary carcinoma of the thyroid. Oncology 67:397-402
21. Boltze C, Zack S, Quednow C, Bettge S, Roessner A, Schneider-Stock R 2003 Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathol Res Pract 199:399-404
22. Elisei R, Shiohara M, Koeffler HP, Fagin JA 1998 Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 83:2185-2193
23. Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB, Saji M, Zeiger MA, Zimmer SG, Baylin SB 1998 Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res 58:2063-2066
24. Husmark J, Heldin NE, Nilsson M 1999 N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. Int J Cancer 83:692-699
25. Rocha AS, Soares P, Seruca R, Maximo V, Matias-Guiu X, Cameselle-Teijeiro J, Sobrinho-SimoesM2001 Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. J Pathol 194:358-366
26. Kato N, Tsuchiya T, Tamura G, Motoyama T 2002 E-cadherin expression in follicular carcinoma of the thyroid. Pathol Int 52:13-18
27. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS 2004 GST profiling may be useful in the screening for thyroid nodule malignancy. Cancer Lett 209:129-137
28. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG 2003 Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9:2912-2919
29. Kang GH, Lee S, Kim JS, Jung HY 2003 Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Invest 83:519-526
30. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D 2000 Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60:892-895
31. Nakatsuka S, Takakuwa T, Tomita Y, Miwa H, Matsuzuka F, Aozasa K 2000 Role of hypermethylation of DAP-kinase CpG island in the development of thyroid lymphoma. Lab Invest 80:1651-1655
32. Baylin SB, Hoppener JW, de Bustros A, Steenbergh PH, Lips CJ, Nelkin BD 1986 DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 46:2917-2922
33. Fendrich V, Slater EP, Heinmoller E, Ramaswamy A, Celik I, Nowak O, Chaloupka B, Gerdes B, Bartsch DK 2005 Alterations of the tissue inhibitor of metalloproteinase-3 (TIMP3) gene in pancreatic adenocarcinomas. Pancreas 30:e40-e45
34. Darnton SJ, Hardie LJ, Muc RS, Wild CP, Casson AG 2005 Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int J Cancer 115:351-358
35. Wild A, Ramaswamy A, Langer P, Celik I, Fendrich V, Chaloupka B, Simon B, Bartsch DK 2003 Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J Clin Endocrinol Metab 88:1367-1373
36. Kim HP, Lee MS, Yu J, Park JA, Jong HS, Kim TY, Lee JW, Bang YJ 2004 TGF-β1 (transforming growth factor-β1)-mediated adhesion of gastric carcinoma cells involves a decrease in Ras/ERKs (extracellular-signal-regulated kinases) cascade activity dependent on c-Src activity. Biochem J 379:141-150
37. Ammanamanchi S, Brattain MG 2004 Restoration of transforming growth factor-β signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J Biol Chem 279:32620-32625
38. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627
39. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D 2004 BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:1365-1368
40. Xu X, Quiros RM, Gattuso P, Ain KB, PrinzRA2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567
41. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH 2004 Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10:2761-2765
42. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
43. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH 2003 A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63:1727-1730
44. Ha PK, Califano JA 2003 The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med 14:363-369
45. Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG, Brock MV 2004 Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res 10:5131-5136
46. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S 2001 Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer. Oncogene 20:3348-3353
47. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D 2001 Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93: 1747-1752
48. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH 2004 BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 17:1359-1363
49. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP, Hoang-Vu C 2003 Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22:3806-3812
50. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ 2003 Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery 134: 902-908; discussion, 909
51. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV 2003 Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 10:437-450
52. Carling T, Du Y, Fang W, Correa P, Huang S 2003 Intragenic allelic loss and promoter hypermethylation of the RIZ1 tumor suppressor gene in parathyroid tumors and pheochromocytomas. Surgery 134:932-939; discussion, 939-940
53. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, RashidA2003 CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22:924-934
54. Youssef EM, Estecio MR, Issa JP 2004 Methylation and regulation of expression of different retinoic acid receptor β isoforms in human colon cancer. Cancer Biol Ther 3:82-86
55. Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, Han J, Park J, Kim DH 2004 Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 22:2363-2370
56. Bandyopadhyay D, Medrano EE 2003 The emerging role of epigenetics in cellular and organismal aging. Exp Gerontol 38:1299-1307
57. Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, Kane CJ, Carroll PR, Igawa M, DahiyaR2004 Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun 321:455-461
58. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH 2003 Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163: 1371-1378
59. Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J, Park J 2003 Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 63:3743-3746
60. Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J, Herman JG, Esteller M, Matias-Guiu X, Palacios J 2003 Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 199:471-478
61. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, Carbone A, Gaidano G 2004 Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89:154-164
62. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, Cigudosa JC, Huang TH, Esteller M 2003 Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 22:6335-6345
63. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P 2003 DNA methylation of RASSF1A, HIN-1, RAR-β, cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107:970-975